Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Return on Equity (2018 - 2025)

Cue Biopharma's Return on Equity history spans 8 years, with the latest figure at 2.37% for Q3 2025.

  • For Q3 2025, Return on Equity fell 52.0% year-over-year to 2.37%; the TTM value through Sep 2025 reached 2.37%, down 52.0%, while the annual FY2024 figure was 1.46%, 50.0% down from the prior year.
  • Return on Equity for Q3 2025 was 2.37% at Cue Biopharma, up from 3.1% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.6% in Q1 2021 and bottomed at 3.31% in Q1 2025.
  • The 5-year median for Return on Equity is 1.01% (2023), against an average of 1.35%.
  • The largest annual shift saw Return on Equity rose 17bps in 2021 before it plummeted -186bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.68% in 2021, then plummeted by -34bps to 0.9% in 2022, then tumbled by -37bps to 1.24% in 2023, then crashed by -50bps to 1.86% in 2024, then dropped by -27bps to 2.37% in 2025.
  • Per Business Quant, the three most recent readings for CUE's Return on Equity are 2.37% (Q3 2025), 3.1% (Q2 2025), and 3.31% (Q1 2025).